Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.

Abstract

A 43-year-old woman with autosomal-dominant polycystic kidney disease (ADPKD) received octreotide for 12 months, and this was associated with a 6.3% reduction in liver volume, an 8% reduction in total kidney volume and stabilization of renal function. There was also a reduction of cyst size in fibrocystic disease of breast. These data suggest that the cyst fluid accumulation in different organs from patients with ADPKD is a dynamic process which can be reversed by octreotide. This is the first report of a case of simultaneous reduction in hepatic, renal and breast cystic volume with preservation of renal function in a patient with ADPKD receiving octreotide.

• Authors: Ramón Peces, Emilio Cuesta-López, Carlos Peces, Virginia Pérez-Dueñas, Cristina Vega-Cabrera, Rafael Selgas
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 43 Issue 2 Pg. 565-9 (Jun 2011) ISSN: 1573-2584 [Electronic] Netherlands
• PMID: 20449653 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Octreotide

Topics

• Adult
• Breast Cyst (drug therapy, etiology)
• Cysts (drug therapy, etiology)
• Female
• Humans
• Kidney Diseases, Cystic (drug therapy, etiology)
• Liver Diseases (drug therapy, etiology)
• Octreotide (therapeutic use)
• Polycystic Kidney, Autosomal Dominant (complications)